Patent ID: 7329660
Filing Date: 2008-02-12
Classification: A61K,A61P,C07D

Abstract:
1. A method of treating leukemias by inhibiting VEGF-receptor tyrosine kinase activity comprising administering a compound of formula I, wherein r is 0 to 2, n is 0 to 3 R a) are independently in each case a lower alkyl; b) together form a bridge of subformula I*, wherein a bond characterizing said bridge is achieved via two terminal C atoms of R m is 0 to 4, or c) together form a bridge of subformula I**, wherein one or two of the ring members T G is —C(═O)—, —CHF—, —CF —CH A, B, D, E and T are independently N or CH subject to the proviso that at least one and not more than three of these radicals are N; Q is lower alkyl, lower alkoxy, or halogen; R X is imino, oxa or thia; Y is hydrogen, aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and Z is mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherified or esterified hydroxy, nitro, cyano, carboxy, esterified carboxy, alkanoyl, carbamoyl, N- mono- or N,N-disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl lower alkylthio, alkylphenylthio, phenylsulfinyl, phenyl-lower alkylsulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower alkylsulfonyl, alkylphenylsulfonyl, or selected from the group consisting of ureido, halo-lower alkylthio, halo-lower alkansulfonyl, pyrazolyl, lower-alkyl pyrazolyl and C and wherein the bonds characterized in subformula I* by a wavy line are either single or double bonds; or an N-oxide of said compound, wherein 1 or more N atoms carry an oxygen atom; or a pharmaceutically acceptable salt thereof.